The renin-angiotensin system is upregulated in pregnant women and may play a role in myometrial hypertrophy during pregnancy. We examined whether angiotensin II could induce myometrial protein synthesis as determined by 3 H-leucine incorporation in an immortalized human myometrial smooth muscle cell line (ULTR cells). The effects of angiotensin II were mediated by NADPH oxidase because diphenylene iodonium abolished angiotensin II-induced protein synthesis. We investigated gene expression and cellular localization of NADPH oxidase isoforms in ULTR cells and confirmed expression of NOX1, NOX4, and NOX5 in myometrial tissue. Angiotensin II induced a cellular redistribution and upregulation of NOX5 protein without altering NOX1 and NOX4 expression. It seems the effect of angiotensin II relies on the type 1 receptor (AT1), because losartan significantly blocked angiotensin II-induced increase in 3 H-leucine incorporation. We conclude that NADPH oxidase mediates angiotensin II-stimulated protein synthesis downstream of AT1 in myometrium smooth muscle cells. growth factors, oxidative stress, pregnancy, uterus
INTRODUCTION
Myometrial hypertrophy is a physiological process occurring during pregnancy to accommodate fetal growth and the need for contraction at delivery. Growth factors, sex hormones, and cytokines are known to stimulate uterine smooth muscle growth in normal pregnancy or in myometrial pathologies, such as fibrosis [1] . The renin-angiotensin system is upregulated in pregnant women [2] [3] [4] [5] . However, the potential role of angiotensin II (Ang II) on myometrial growth has not been well defined. Molecular cloning has validated the existence of two Ang II receptors: AGTR1 (AT1) and AGTR2 (AT2) [6] [7] [8] [9] . AT1 mediates most biological effects of Ang II, including increase of muscular tone and cell growth, whereas AT2 counteracts AT1 by causing growth arrest or apoptosis in most tissues [6, 10] . However, there is also evidence that AT2 is hypertrophic and shares common signaling pathways with AT1 (see review by Inagami and Senbonmatsu [11] ). We have postulated that Ang II may exert growth-modulatory effects on the myometrium during pregnancy via AT1 and downstream signaling pathways. The ULTR cell is an immortalized uterine smooth muscle cell line, and it has been widely used for studying myometrial signal transduction and is reported to give more reproducible data than primary myometrial cells [12] [13] [14] . It is feasible, then, to study the mechanism of Ang II-induced myometrial hypertrophy in ULTR cells, particularly if they express both AT1 and AT2 receptors.
Reactive oxygen species (ROS) plays an important role in growth regulation in many tissue types. NADPH oxidase was first described in phagocytes as the source of ROS during the respiratory burst. This enzyme consists of five unique peptides: two membrane-bound peptides of 22 kDa and 91 kDa (CYBA or p22-PHOX, and CYBB or GP91-PHOX, respectively), which make up the redox pathway, and four cytosolic components of 40 kDa, 47 kDa, 67 kDa (NCF4 or p40phox, NCF1 or p47phox, and NCF2 or p67phox, respectively), and a small GTPase Rac [15] . The catalytic core unit (NOX) GP91-PHOX contains binding sites for NADPH, flavin, and heme. Molecular cloning of human GP91-PHOX (CYBB or NOX2) has revealed the NOX superfamily genes. Currently, seven NOX homologs have been identified, including NOX1 through NOX5, DUOX1, and DUOX2 [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . There are distinct expression patterns, mechanisms of activation, and physiological functions for the NOX isoforms [27] [28] [29] . Particularly, NOX1 is activated by growth factors, such as Ang II and epidermal growth factor (EGF), and requires distinct cytosolic subunits NOXO1 and NOXA1 (homologs of p47phox and p67phox, respectively) for a high level of ROS generation [24] . NOX4 forms a complex with p22-PHOX but does not require cytosolic subunits for activation [30] . On the other hand, NOX5 is activated by elevated cytosolic Ca 2þ via its N terminus-located EF hands [16, 24, 31] . We hypothesized that NOX isoforms are expressed in myometrium, and NOX1 may be involved in Ang II-induced hypertrophy. In our study, the effects of Ang II on NOX expression and uterine hypertrophy were investigated in the ULTR uterine smooth muscle cell line.
MATERIALS AND METHODS

Materials
Unless specified otherwise, common laboratory chemicals and reagents were purchased either from Fisher Scientific (Pittsburgh, PA) or from SigmaAldrich (St. Louis, MO). Media and additives for cell culture, as well as reagents for RNA analysis were purchased from Invitrogen (Carlsbad, CA).
Cell Culture
The ULTR cell line was a gift from Dr. James K. McDougall at the Fred Hutchinson Cancer Research Center (Seattle, WA). The institutional safety and ethics guidelines were met for using these immortalized cells, and cells from passages 22 to 29 were employed in the current study. The cells were grown under standard culture conditions on collagen IV-coated (BD Biosciences, San Jose, CA) plastic surfaces in Dulbecco modified Eagle medium (DMEM) supplemented with 10% bovine serum and 13 antibiotic-antimycotic solution at 378C with 5% CO 2 in air.
Western Blot Analysis
Rabbit anti-AT1 and goat anti-AT2, NOX4, and b-actin (ACTB) polyclonal antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-NOX1 and anti-NOX5 polyclonal antisera were raised as described previously [32] . ULTR total-cell lysates were extracted with lysis buffer containing 50 mM Tris-HCl (pH 7.2), 150 mM NaCl, 1% Nonidet P-40, 1% Triton X-100, 1 mM Na 3 VO 4 , 1 mM ethylene glycol tetraacetic acid, 1 mM NaF, and 1:50 dilution of protease inhibitor cocktail. Proteins were resolved by 10% SDS-PAGE followed by electroblotting at 200 mA overnight to a polyvinylidene difluoride (PVDF) membrane. The PVDF membrane was immunoblotted with a 1:1000 dilution of primary antibodies at 48C overnight, followed by 1:2500 dilution of horseradish peroxidaseconjugated secondary antibody at 378C for 1 h, with three washes in between incubations at room temperature. The immunoreaction was detected with enhanced chemiluminescence (Amersham Biosciences, Pittsburgh, PA). Densitometric data from Western blots were obtained with the Alpha Image Software. 
H-Thymidine Incorporation
To determine changes in DNA and protein synthesis, ULTR cells grown in 24-well plates were washed twice and incubated in serum-free DMEM for 24 h. They were then exposed to fresh medium containing Ang II (0-1000 nM) with or without the presence of either AT1 antagonist losartan (10 lM), AT2 antagonist PD123319 (10 lM), or NADPH oxidase inhibitor diphenylene iodonium (DPI; 50 lM) for 24 h. EGF (10 ng/ml) was employed as a positive control because it is a growth factor and activates NOX1. During the last 4 h of incubation, 1 lCi/well 3 H-leucine or 3 H-thymidine (PerkinElmer NEN, Waltham, MA) was added to the media. At the end of the experiment, the media were aspirated, and the cells were washed twice with PBS followed by incubation with ice-cold 10% trichloroacetic acid for 30 min. After two additional washes of 5% trichloroacetic acid, the cells were solubilized with 500-ll solution containing 1% SDS in 0.1 N NaOH. Radioactivity in 200-ll aliquots of the resulting cell lysates was quantitated by scintillation counting.
Total RNA Isolation, RT, and PCR Cloning NOX isoforms and subunits of NADPH oxidase were identified with RT-PCR cloning. Tissues and cell lines known to express one or more NOX isoforms, according to the literature, were selected as positive controls for cloning. They were placenta for NOX5, uterus for NOX4, thyroid for DUOX1 and DOUX2, HEK-293 cells for NOX1, HL-60 cells for NOX2, and Huh-7.5 cells for NOX3. All total RNA samples from tissues were purchased from a commercial source (Stratagene Corp., La Jolla, CA) for the guaranteed quality to assure RT-PCR results. Total RNA from cultured cells was extracted with the RNeasy total RNA isolation kit (Qiagen Inc., Valencia, CA). A total of 1 lg of RNA, as calculated from the absorbance at 260 nm, was treated with 1 unit of RNase-free DNase I to eliminate genomic DNA by reacting in a 10-ll volume for 15 min at room temperature. The reaction was stopped by adding ethylenediaminetetraacetic acid (EDTA) and heating for 10 min at 658C. The first-strand cDNA was synthesized by using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and the SuperScript II reverse transcriptase in a 20-ll reaction which contains dithiothreitol and dinucleotide triphospate (dNTP). Aliquots of 1-ll reaction product were subjected to PCR reaction, which included 2 ll of gene-specific primer pairs and 27 ll of master mixture containing MgCl 2 , dNTP, and Taq polymerase on an Eppendorf MasterCycler for 35 to 40 cycles. The primer sequences are listed in Table 1 . To confirm the result, PCR products were subcloned to topoisomerase-activated pCR 4.0-TOPO vector and transformed into One Shot competent Escherichia coli. The plasmid carrying a PCR product was purified with plasmid mini kit (Qiagen) and sequenced in the University of Cincinnati DNA Core Lab.
Cellular Protein Fractionation
To determine the cellular localization of the NOX protein, cultured ULTR cells were collected by scraping in 0.25 M sucrose solution containing 50 mM HEPES and a 1:50 dilution of the protease inhibitor cocktail. Cells were homogenized with 30 strokes on ice using a type B dounce homogenizer and were centrifuged at 1000 3 g for 15 min. The supernatant was centrifuged at 100 000 3 g for 1 h. The supernatant was collected as the cytosolic fraction, and the protein concentration was determined by bicinchoninic acid assay according to the manufacturer's instructions (Thermo Fisher Scientific, Rockford, IL). The pellet was dissolved in Laemmli sample buffer to yield the membranous fraction.
Immunohistochemistry
ULTR cells grown and stimulated in slide chambers were washed twice with ice-cold PBS and fixed with 4% paraformaldehyde for 10 min at room temperature, followed by a 0.3% hydrogen peroxide treatment for 5 min. After washing with PBS, the cells were incubated with or without a 1:100 dilution of primary antibodies in PBS containing 1 mg/ml saponin (PBSS) at 48C overnight. After three washes in PBSS for 5 min each at room temperature, the cells were incubated with 1:200 dilution of biotinylated secondary antibody at 378C for 30 min in the Vectastain Elite ABC staining kit (Vector Laboratories, Burlingame, CA). Aminoethyl carbazole (AEC) was used as the peroxidase substrate that forms a red precipitate. The slides were then counterstained in hematoxylin and mounted in 1:9 PBS:glycerol. For fluorescent immunohistochemistry, the slides were processed similarly but with omission of hydrogen peroxide treatment and substitution of AEC development with 1:500 dilution of streptavidin-conjugated Qdot655 (Invitrogen, Carlsbad, CA) at room temperature for 30 min. Slides were then washed, mounted in 1:9 PBS:glycerol, and viewed with an XF305 Qdot 655 filter set on a Zeiss digital camera with the images captured with fixed exposure time using AxioVision software.
Uterine biopsy samples were collected from pregnant women who underwent elective cesarean delivery under an Institutional Review Board protocol following patient consent. These samples were taken from the uterine incision site and were flash frozen in liquid nitrogen and stored at À808C to serve as a tissue bank. Immunohistochemical staining of NOX proteins was performed in five deidentified samples from term pregnant women. The tissues were embedded in Tissue-Tek O.C.T. Embedding Compound and sectioned at 7 lm on a cryostat. The tissue sections were air dried for 1 h at room temperature and rehydrated in PBS for 20 min. The sections were then fixed with 4% paraformaldehyde for 10 min at room temperature, followed by the same procedures for AEC development, except that saponin was omitted in the solutions.
Data Analysis
Data were presented as mean 6 SEM. One-way ANOVA analysis with Turkey posthoc tests was employed to determine the effects of various 
RESULTS
The uterus is one of the few organs that retain AT2 expression after birth, and it has been reported that AT1 and AT2 coexist in the pregnant myometrium [3, [33] [34] [35] [36] . We examined protein expression of AT1 (46 kDa) and AT2 (68 kDa) in ULTR cells with Western blot analysis and found that they were expressed at comparable levels. There was no apparent change in the expression level when ULTR cells were exposed to Ang II at a concentration range from 0 to 1000 nM for 24 h (Fig. 1A) . Therefore, the ULTR cell is a suitable cellular model for the current study. ULTR cells were then exposed to 0-1000 nM Ang II for 24 h in order to determine its effect on protein synthesis. We observed a concentrationdependent increase of 3 H-leucine incorporation (Fig. 1B) . At 1000 nM, the effect was 202% 6 15% of the basal level (P , 0.05). As a positive control, treating ULTR cells with 10 ng/ml EGF for 24 h also increased 3 H-leucine incorporation (P , 0.05). It has been reported that Ang II plasma concentrations reach 100-1000 nM in pregnant women [5] . We therefore employed 100 and 1000 nM Ang II in further experiments. Ang II did not increase 3 H-thymidine incorporation at either 100 or 1000 nM (Fig. 1C) .
NADPH oxidase has been shown to mediate Ang II-induced vascular smooth muscle hypertrophy. Indeed, we observed that Ang II-induced 3 H-leucine incorporation was attenuated back to the basal level by a nonspecific NADPH oxidase inhibitor, DPI (50 lM; P , 0.001), in ULTR cells ( Fig. 2A) . We subsequently employed nonquantitative RT-PCR analysis to determine the expression of NOX isoforms in ULTR cells. As shown in Figure 2B , ULTR cells expressed NOX1, NOX4, and NOX5 abundantly, with lower expression of NOX2, DUOX1, and DUOX2. NOX3 was detected both in the positive control (Huh-7.5 cell) and in ULTR cells with two-round nested PCR, employing 1 ll of 1:10 diluted PCR product from the firstround PCR reaction as the template for the second-round PCR reaction (data not shown). In addition, we examined expression of other subunits of NADPH oxidase. As shown in Figure 2C , both the uterus (lane 3) and ULTR cells (lane 4) expressed p22-PHOX (CYBA), p67phox (NCF2), and RAC1/2. There seemed to be a lack of expression of NOXO1 and NCF4 (p40phox) and low expression of NCF1 (p47phox) and NOXA1 in ULTR cells.
We further examined the cellular localization of the NOX1, NOX4, and NOX5 proteins by cell fractionation and Western blot analysis. We observed that NOX1 was localized in the membrane fraction, NOX4 in the cytosol, and NOX5 in both fractions (Fig. 3A) . Expression of these NOX proteins in myometrial smooth muscle cells was confirmed with immunohistochemical analysis on tissue biopsy samples obtained from term pregnant women (Fig. 3B) . We observed that NOX1 and NOX4 were diffusely expressed in the uterus, whereas NOX5 was more confined to the decidua and the myometrial smooth muscle.
With fluorescent immunohistochemistry, we confirmed the distribution patterns of NOX isoforms in untreated ULTR cells (Fig. 4A) . When ULTR cells were exposed to 100 nM Ang II for 24 h, we observed a profoundly increased expression and redistribution of NOX5 to the plasma membrane, whereas there was no apparent change in NOX1 and NOX4 cellular localization. The increased expression of NOX5 protein along with increased cellular size was induced by Ang II, as observed with immunohistochemistry employing AEC development (Fig. 4B) . There seems to be a higher basal NOX1 expression, whereas Ang II failed to induce upregulation of NOX1. We then further confirmed with Western blot analysis that Ang II induced NOX5 protein expression in ULTR cells. A 63% 6 12% induction of NOX5 protein was observed by 1000 nM Ang II stimulation for 24 h in three independent experiments (P , 0.01). However, NOX1 and NOX4 protein levels were not changed (Fig. 4C) .
To determine the receptor subtype that mediates Ang II's effect, ULTR cells were stimulated with 1000 nM Ang II for NOX AND MYOMETRIUM HYPERTROPHY 307 24 h in the presence or absence of either the specific AT1 antagonist losartan (10 lM) or an AT2 antagonist, PD123319 (10 lM). We observed that Ang II had a main effect of increasing 3 H-leucine incorporation (P , 0.05), whereas losartan did not (P ¼ 0.773), although it slightly increased basal 3 H-leucine incorporation. However, the effect of Ang II in inducing leucine incorporation was attenuated by losartan treatment (P , 0.001; Fig. 5 ). On the other hand, no effect of 10 lM PD123319 was observed (data not shown).
DISCUSSION
Previous morphologic studies suggested that pregnancy enlarges the uterus mostly by myometrial hypertrophy with minor hyperplasia [37] . Research on cardiac myocyte hypertrophy and vascular remodeling suggests that oxidative and nitrosative stresses play an important role [38, 39] . There is no doubt that pregnancy, with a steep increase in maternal metabolism, ischemia/reperfusion of the uteroplacental unit, and fetal growth-induced mechanical stretch, will be accompanied by increased uterine ROS generation. However, there is a lack of description of ROS generation at the tissue level. Ang II has been shown, both in vivo and in vitro, to be one of the most potent stimuli of NOX1 activation [40] [41] [42] [43] . Long-term infusion of Ang II caused vascular and cardiac hypertrophy in rats, along with an increased expression of several NOX isoforms (NOX1, NOX2, and NOX4) and increased endothelial ROS generation [44] . On the other hand, NOX4 was downregulated by Ang II as well as culture conditions that promoted cell growth in vascular smooth muscle cells [45] . Blockade of NADPH oxidase with DPI or transfection of antisense CYBA (p22-PHOX) has been shown to inhibit Ang IIinduced vascular hypertrophy [40, 46] . We demonstrated with RT-PCR the expression pattern of NOX genes in ULTR cells and confirmed that the NOX 1, 4, and 5 proteins are expressed in the human myometrium [17, 24] . At present, there are no in vivo data directly supporting a physiological role of NOX in the growth of the gravid uterus.
We were surprised that our finding does not support a NOX1-dependent mechanism in Ang II-induced hypertrophy in ULTR cells, because we did not observe either upregulation or redistribution of NOX1 upon Ang II treatment. There was also low or lack of gene expression of both NCF1 and NOXO1, which have been shown to be required for NOX1 activation in vascular smooth muscle cells [47] . Alternatively, a higher basal NOX1 expression may result from the presence of extracellular matrix components, such as collagen IV (data not shown). This may have prevented further NOX1 activation by Ang II. Indeed, extracellular matrix components have been shown to actively participate in cell differentiation processes [48] ; however, their role in NOX signaling in the myometrium is not clear. Because we did not observe changes of NOX4 protein upon Ang II stimulation, we do not believe it plays a role in Ang II-induced ULTR cell protein synthesis.
In comparison with NOX1 and NOX4, the physiological role of NOX5 is less well known. NOX5 was found to mediate platelet-derived growth factor-induced aortic smooth muscle proliferation [49] . NOX5 expression is increased in the blood vessels with coronary artery disease [50] . Expression and activation of NOX5 have been documented in cancer cells [28, 51, 52] . As far as we are aware, this is the first evidence that Ang II induced both upregulation and translocation of NOX5 protein. Although our data suggest that NOX5 mediates the effect of Ang II on protein synthesis in ULTR cells, definitive proof is prevented by the lack of commercially available NOX isoform-specific inhibitors. This ULTR cell line has low transfection efficiency (about 10%) and tends to develop replicative senescence, which would limit application of NOX5-specific siRNA. Further investigation of the Ang IIinduced NOX5 cycling and signal transduction pathways in the myometrium is clearly needed. Currently, there is a renewed interest in the role of the reninangiotensin system in the physiology of pregnancy and the pathology of hypertensive pregnancies. The uteroplacental renin-angiotensin system may have several important functions, including endometrial regeneration, decidualization, and implantation. It participates in the regulation of the uteroplacental blood flow, prostaglandin synthesis, and steroid secretion [4] . Concentrations of Ang II increase 4.5-fold over the nonpregnant level in pregnant sheep [53] . In humans, the Ang II level in the maternal circulation in pregnancy was reported to be 700 nM [5] . This leads to growth and tissue remodeling in essential organs; however, it could also contribute to pregnancy-related cardiovascular pathologies. Interestingly, the Ang II receptors in myometrium are differentially expressed before and during pregnancy: AT2 predominates in the nonpregnant state, and a switch of myometrial receptor subtype from AT2 to AT1 occurs during pregnancy so that they coexist in comparable levels [3, 33, 35, 36, 54] . In vitro, myometrium obtained from pregnant, but not prepregnant, sheep contracts in response to Ang II treatment, which is mediated by AT1 [34] . However, the role of Ang II in myometrial contraction could be limited in pregnant women in vivo. Prostaglandin E synthase mRNA or protein level in myometrium did not change with gestation or labor [55] . Vascular prostaglandin synthesis is induced by Ang II [56] , whereas prostaglandin E2 has been found to counteract the effect of Ang II on activation of NADPH oxidase and vasoconstriction in a mouse model [57] . In addition, high Ang II concentrations may result in agonist-induced receptor internalization and/or desensitization [58, 59] . This may also explain the moderate effect of Ang II on myometrium protein synthesis/hypertrophy seen in the current model. Alternatively, there might be other feedback mechanisms not yet studied in this model.
It is acknowledged that the role of the renin-angiotensin system in gestational physiology is far more complex. NOX AND MYOMETRIUM HYPERTROPHY Formation of homo-or hetero-oligomers is commonly found among G protein-coupled receptors and has complicated our understanding of the signaling networks [60] . It has been found that AT1-mediated signaling was activated and enhanced by heterodimerization with the bradykinin B 2 receptor [61] .
Homodimerization and heterodimerization in the AT1 and AT2 have been shown to modulate the effect of Ang II, perhaps in a tissue-specific manner [60, 62] . We have observed a basal stimulation of 3 H-leucine incorporation of 18% by 10 lM AT1 antagonist losartan and a more profound stimulation of 32% by 10 lM AT2 antagonist PD123319. We have not been able to demonstrate the physical associations of AT1 and AT2 in this model, although it is possible that AT2 was functioning as an AT1 antagonist through conformation changes and receptor internalization [62] . Therefore, application of PD123319 may stimulate AT1 signaling while blocking additional Ang II binding to AT1. It has been shown recently that Ang II has intracrine activities by activating nuclear AT1 and AT2 [63] [64] [65] . The complexity of this system also increases with discovery of the new members (i.e., ACE2 and the Ang-(1-7) receptor Mas [66, 67] ) and their interactions during gestation [68] .
Taken together, we have demonstrated the expression of NOX isoforms in a human myometrial smooth muscle cell line. NADPH oxidase activity is responsible for Ang II-induced protein synthesis, potentially being one of the mechanisms contributing to myometrial hypertrophy in pregnant women. It is likely that AT1 mediates the hypertrophic responses of Ang II in the myometrium, whereas we postulate a cross-talk between AT1 and AT2. On the other hand, there may be changes in other aspects of the redox signaling that may play a role in myometrium remodeling during gestation, which await further investigation. 
